Daily Reporter

Today Don't Miss

Today Don't Miss

Are we reaching a turning point in metastatic prostate cancer?

At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…

Read More

RAS: a moving target

Ras oncogene means different things to different tumours in different tissues. Step away from RAS itself and we enter a universe of complex and diverse biological processes that Ras oncogene orchestrates. In my view, deep…

Read More





What is fair pricing in oncology?

Finding a balance between price and availability of innovative therapies is complicated. Each stakeholder, from the patient and healthcare systems to research and development (R&D) companies, has a very different view of fair pricing for…

Read More